Regarding the impact on Sozinibercept trail, my understanding is that its mechanism of action differs from that of Eylea. Given this distinction, is it more of a competitive concern, or do they merely coexist within the trial framework? The decline in the share price suggests that this situation may not be good for OPT.
Regarding the impact on Sozinibercept trail, my understanding is...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $467.8M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.5¢ | $176.6K | 463.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 121324 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 90033 | 3 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |